Hoffmann Olaf, Gold Ralf, Meuth Sven G, Linker Ralf A, Skripuletz Thomas, Wiendl Heinz, Wattjes Mike P
Department of Neurology, Alexianer St. Josefs-Krankenhaus Potsdam, Allee nach Sanssouci 7, 14471 Potsdam, Germany; Medizinische Hochschule Brandenburg Theodor Fontane, Neuruppin, Germany.
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Ther Adv Neurol Disord. 2024 Feb 7;17:17562864241229325. doi: 10.1177/17562864241229325. eCollection 2024.
Magnetic resonance imaging (MRI) of the brain and spinal cord plays a crucial role in the diagnosis and monitoring of multiple sclerosis (MS). There is conclusive evidence that brain and spinal cord MRI findings in early disease stages also provide relevant insight into individual prognosis. This includes prediction of disease activity and disease progression, the accumulation of long-term disability and the conversion to secondary progressive MS. The extent to which these MRI findings should influence treatment decisions remains a subject of ongoing discussion. The aim of this review is to present and discuss the current knowledge and scientific evidence regarding the utility of MRI at early MS disease stages for prognostic classification of individual patients. In addition, we discuss the current evidence regarding the use of MRI in order to predict treatment response. Finally, we propose a potential approach as to how MRI data may be categorized and integrated into early clinical decision making.
Ther Adv Neurol Disord. 2024-2-7
CNS Drugs. 2004
Diagnostics (Basel). 2024-5-28
Patient Prefer Adherence. 2024-2-22
Curr Neurol Neurosci Rep. 2023-9
Nat Rev Neurol. 2023-5
Nat Rev Neurol. 2023-3